Crohn
1
1
2
1/- 4 2
Crohn
( )
,
: 20-30 60-70
-
Bowel rest
Anti-TNF
Infliximab
Adalimumab
Certolizumab pegol
Anti-integrin 4 Vedolizumab
Natalizumab
Infliximab
EMA approval: 1999
mAb IgG1 -
:
Crohn
:
, ,
:
, , , , ,
Adalimumab
EMA approval: 2003
mAb IgG1
TNF
:
Crohn
:
infliximab
:
, , , -, , ,
Certolizumab pegol
FDA approval: 2008
- (Kawalek et al, 2013)
The role of selected integrinsin lymphocyte migration
Natalizumab
FDA approval: 2008
-4
PML (JC virus) EMA
MS
Vedolizumab
EMA approval: 2014
mAb IgG1 -47
:
Crohn, anti-TNF ( )
:
,
:
, ,
CD + UC = IBD
anti-TNF anti-integrin 4 nti-TNF: infliximab, adalimumab
Anti-integrin 4: vedolizumab
Top Related